Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline.
Three patients with premenstrual dysphoric disorder (PMDD) and recurrent vulvovaginal candidiasis (VVC) underwent sertraline therapy (Tresleen, a selective serotonin-reuptake inhibitor; Pfizer) for PMDD. During sertraline intervention, patients had no recurrent episodes of acute VVC. Antifungal activity was observed for sertraline against various isolates of Candida species.
Lass-Flörl
C
C
Institutes of Hygiene and Social Medicine, University of Innsbruck, Austria. Cornelia.Lass-Floerl@uibk.ac.at
Dierich
M P
MP
Fuchs
D
D
Semenitz
E
E
Ledochowski
M
M
D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D005260:Female; D006801:Humans; D011293:Premenstrual Syndrome / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D020280:Sertraline / Q000494:pharmacology / Q000627:therapeutic use*
D000935:Antifungal Agents; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline